SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Any info about Iomega (IOM)? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Pearson who wrote (38033)12/1/1997 12:11:00 PM
From: Spank  Read Replies (1) | Respond to of 58324
 
** OT ** WLA: Alex Brown is your culprit--cut to "buy" from s.b. (eom)



To: Linda Pearson who wrote (38033)12/1/1997 12:16:00 PM
From: W. Clinton Terry  Read Replies (2) | Respond to of 58324
 
Linda:

I am watching and it does not look like it wants to bounce .. at all. I could not find any news other than the downgrades and their relabeling their diabetes drug, which I found to be rather responsible given the difficulties discovered with the Glaxo-Wellcome diabetes drug. The eps downgrade comes to about 5-6 percent whereas the drop in the share price is around 17 percent.

Clinton



To: Linda Pearson who wrote (38033)12/1/1997 12:37:00 PM
From: Dave Krishna  Respond to of 58324
 
OT: Re: Warner Lambert

Linda,

From my own experience I can tell you that Rezulin sales have been
strong and apparently future revenues from this product were
already priced firmly in the stock. The news about the adverse
effects on the liver is not good at all especially with all the
recent headlines of the obesity drugs. If it is any consolation,
Lipitor is doing extremely well, much better than Zocor, Pravachol.

Regards,

Dave


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News